HRP20211599T1 - Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik - Google Patents
Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik Download PDFInfo
- Publication number
- HRP20211599T1 HRP20211599T1 HRP20211599TT HRP20211599T HRP20211599T1 HR P20211599 T1 HRP20211599 T1 HR P20211599T1 HR P20211599T T HRP20211599T T HR P20211599TT HR P20211599 T HRP20211599 T HR P20211599T HR P20211599 T1 HRP20211599 T1 HR P20211599T1
- Authority
- HR
- Croatia
- Prior art keywords
- particles
- use according
- powder formulation
- mixture
- disease
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 16
- 238000009472 formulation Methods 0.000 title claims 11
- 239000000843 powder Substances 0.000 title claims 11
- 230000001078 anti-cholinergic effect Effects 0.000 title 1
- 239000003246 corticosteroid Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000002245 particle Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 229960002462 glycopyrronium bromide Drugs 0.000 claims 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims 3
- 150000004683 dihydrates Chemical class 0.000 claims 2
- 239000010419 fine particle Substances 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical group O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 claims 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 239000011362 coarse particle Substances 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 229960002848 formoterol Drugs 0.000 claims 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims 1
- 229940125369 inhaled corticosteroids Drugs 0.000 claims 1
- 229940127212 long-acting beta 2 agonist Drugs 0.000 claims 1
- 235000019359 magnesium stearate Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 210000002345 respiratory system Anatomy 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (9)
1. Formulacija praška za inhalaciju za upotrebu inhalacijom u sprječavanju i/ili liječenju upalne i/ili opstruktivne bolesti dišnih puteva, time da spomenuti prašak sadrži sljedeće:
(A) nosač koji sadrži sljedeće:
(a) udio grubo usitnjenih čestica fiziološki prihvatljivog ekscipijensa koji ima prosječnu veličinu čestica najmanje 175 µm, te
(b) udio fino usitnjenih čestica koji se sastoje od smjese 90 do 99.5 posto po masi čestica fiziološki prihvatljivog ekscipijensa i 0.5 do 10 posto magnezijeva stearata, s tim da najmanje 90% spomenutih čestica ima volumni promjer manji od 15 µm,
pri čemu maseni omjer spomenutih grubo usitnjenih čestica jest 5:95 do 30:70, i
(B) fino usitnjene čestice glikopironijeva bromida, formoterol-funarat dihidrata te beklometoazon-dipropionata kao aktivne tvari,
pri čemu se formulacija može dobiti postupkom koji obuhvaća sljedeće korake:
(i) miješanje spomenutog nosača, čestica formoterol-fumatar dihidrata i beklometazon-dipropionata u posudi za mješač s potresivanjem pri brzini rotacije ne manjom od 16 rpm u vremenu ne kraćem od 60 minuta da se dobije prva smjesa, te
(ii) dodavanje čestica glikopironijeva bromida u spomenutu prvu smjesu čime se dobiva druga smjesa i miješanje druge smjese pri brzini rotacije ne većoj od 16 rpm u vremenu ne većem od 40 minuta, te
pri čemu je udio srednjefino usitnjenih čestica glikopironijeva bromida veći od 25%.
2. Formulacija praška za upotrebu prema patentom zahtjevu 1, naznačena time da je udio srednjefino usitnjenih čestica između 28 i 40%.
3. Formulacija praška za upotrebu prema patentom zahtjevu 1 ili 2, naznačena time da je upalna i/ili opstruktivna bolest dišnih puteva odabrana iz sljedeće skupine: kronična opstruktivna bolest pluća (COPD), astma i kronični bronhitis.
4. Formulacija praška za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time da je bolest odabrana od sljedećih: ozbiljna i/ili vrlo ozbiljna opstruktivna bolest pluća (COPD).
5. Formulacija praška za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 4, naznačena time da je za provođenje liječenja pacijenata s COPD čiji su simptomi ograničen protok zraka i povijest pogoršanja.
6. Formulacija praška za upotrebu prema bilo kojem od patentnih zahtjeva 1 do 3, naznačena time da bolest jest perzistetna astma ili astma koja nije kontrolirana srednjim ili visokim dozama inhaliranih kortikosteroida u kombinaciji s dugo djelujućim beta-2-agonistima.
7. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da se u koraku (i) miješanje provodi pri brzini rotacije u rasponu između 16-32 rpm u vremenu između 60 i 120 minuta.
8. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time fiziološki prihvatljiv ekscipijens jest alfa-laktoza monohidrat.
9. Formulacija praška za upotrebu prema bilo kojem od prethodnih patentnih zahtjeva, naznačena time da grubo usitnjene čestice imaju maseni promjer u rasponu od 210 i 360 µm.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15194661 | 2015-11-16 | ||
| EP20156815.1A EP3689379B1 (en) | 2015-11-16 | 2016-11-14 | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211599T1 true HRP20211599T1 (hr) | 2022-01-07 |
Family
ID=54548063
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211599TT HRP20211599T1 (hr) | 2015-11-16 | 2016-11-14 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
| HRP20200571TT HRP20200571T1 (hr) | 2015-11-16 | 2020-04-08 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200571TT HRP20200571T1 (hr) | 2015-11-16 | 2020-04-08 | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik |
Country Status (32)
| Country | Link |
|---|---|
| US (3) | US10086003B2 (hr) |
| EP (2) | EP3377109B1 (hr) |
| JP (1) | JP6942126B2 (hr) |
| KR (1) | KR20180082442A (hr) |
| CN (1) | CN108348614B (hr) |
| AR (1) | AR106687A1 (hr) |
| AU (1) | AU2016357988B2 (hr) |
| CA (1) | CA3005291C (hr) |
| CL (1) | CL2018001297A1 (hr) |
| CO (1) | CO2018005139A2 (hr) |
| DK (2) | DK3689379T3 (hr) |
| EA (1) | EA037346B1 (hr) |
| ES (2) | ES2890409T3 (hr) |
| GE (1) | GEP20207178B (hr) |
| HK (1) | HK1256859A1 (hr) |
| HR (2) | HRP20211599T1 (hr) |
| HU (2) | HUE056402T2 (hr) |
| IL (1) | IL259327B (hr) |
| MA (1) | MA52437A (hr) |
| MX (1) | MX2018005979A (hr) |
| MY (1) | MY198321A (hr) |
| PE (1) | PE20181377A1 (hr) |
| PH (1) | PH12018501023B1 (hr) |
| PL (2) | PL3689379T3 (hr) |
| PT (2) | PT3377109T (hr) |
| SA (1) | SA518391574B1 (hr) |
| SG (2) | SG10201912090UA (hr) |
| SI (2) | SI3689379T1 (hr) |
| TW (1) | TWI729025B (hr) |
| UA (1) | UA125173C2 (hr) |
| WO (1) | WO2017085007A1 (hr) |
| ZA (1) | ZA201803167B (hr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110612095A (zh) | 2017-05-11 | 2019-12-24 | 奇斯药制品公司 | 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法 |
| CA3060020A1 (en) | 2017-05-11 | 2018-11-15 | Chiesi Farmaceutici S.P.A. | A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic |
| WO2019060595A1 (en) * | 2017-09-20 | 2019-03-28 | Teva Branded Pharmaceutical Products R&D, Inc. | INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM |
| US11304901B2 (en) * | 2019-08-28 | 2022-04-19 | Anovent Pharmaceutical (U.S.), Llc | Liposome formulation of fluticasone furoate and method of preparation |
| WO2021143785A1 (zh) * | 2020-01-15 | 2021-07-22 | 四川海思科制药有限公司 | 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法 |
| CN111467498A (zh) * | 2020-05-14 | 2020-07-31 | 王兆霖 | 药物组合物制剂 |
| CN117064869A (zh) * | 2023-09-27 | 2023-11-17 | 山东京卫制药有限公司 | 一种胶囊型吸入粉雾剂及其制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20011227A1 (es) | 2000-04-17 | 2002-01-07 | Chiesi Farma Spa | Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros |
| GB0015043D0 (en) | 2000-06-21 | 2000-08-09 | Glaxo Group Ltd | Medicament dispenser |
| SI1658872T2 (sl) | 2002-07-31 | 2019-12-31 | Chiesi Farmacetuici S.P.A. | Inhalator prahu |
| JP2009514779A (ja) * | 2003-07-11 | 2009-04-09 | グラクソ グループ リミテッド | 医薬製剤 |
| GB0410399D0 (en) * | 2004-05-10 | 2004-06-16 | Arakis Ltd | The treatment of respiratory disease |
| SG184964A1 (en) | 2010-04-21 | 2012-11-29 | Chiesi Farma Spa | Process for providing particles with reduced electrostatic charges |
| US9393202B2 (en) | 2013-04-26 | 2016-07-19 | Chiesi Farmaceutici S.P.A | Particle size reduction of an antimuscarinic compound |
| EP3019153B1 (en) | 2013-07-11 | 2018-09-05 | Chiesi Farmaceutici S.p.A. | Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation |
-
2016
- 2016-11-14 HU HUE20156815A patent/HUE056402T2/hu unknown
- 2016-11-14 UA UAA201805272A patent/UA125173C2/uk unknown
- 2016-11-14 DK DK20156815.1T patent/DK3689379T3/da active
- 2016-11-14 SI SI201631330T patent/SI3689379T1/sl unknown
- 2016-11-14 EP EP16801984.2A patent/EP3377109B1/en active Active
- 2016-11-14 HU HUE16801984A patent/HUE050343T2/hu unknown
- 2016-11-14 PT PT168019842T patent/PT3377109T/pt unknown
- 2016-11-14 AR ARP160103472A patent/AR106687A1/es unknown
- 2016-11-14 MY MYPI2018000703A patent/MY198321A/en unknown
- 2016-11-14 CA CA3005291A patent/CA3005291C/en active Active
- 2016-11-14 AU AU2016357988A patent/AU2016357988B2/en active Active
- 2016-11-14 DK DK16801984.2T patent/DK3377109T3/da active
- 2016-11-14 PE PE2018000972A patent/PE20181377A1/es unknown
- 2016-11-14 PL PL20156815T patent/PL3689379T3/pl unknown
- 2016-11-14 GE GEAP201614782A patent/GEP20207178B/en unknown
- 2016-11-14 HR HRP20211599TT patent/HRP20211599T1/hr unknown
- 2016-11-14 EP EP20156815.1A patent/EP3689379B1/en active Active
- 2016-11-14 TW TW105137047A patent/TWI729025B/zh active
- 2016-11-14 SI SI201630738T patent/SI3377109T1/sl unknown
- 2016-11-14 MX MX2018005979A patent/MX2018005979A/es active IP Right Grant
- 2016-11-14 ES ES20156815T patent/ES2890409T3/es active Active
- 2016-11-14 ES ES16801984T patent/ES2789365T3/es active Active
- 2016-11-14 PT PT201568151T patent/PT3689379T/pt unknown
- 2016-11-14 EA EA201890967A patent/EA037346B1/ru unknown
- 2016-11-14 KR KR1020187013284A patent/KR20180082442A/ko unknown
- 2016-11-14 SG SG10201912090UA patent/SG10201912090UA/en unknown
- 2016-11-14 SG SG11201804048WA patent/SG11201804048WA/en unknown
- 2016-11-14 MA MA052437A patent/MA52437A/fr unknown
- 2016-11-14 CN CN201680066805.3A patent/CN108348614B/zh active Active
- 2016-11-14 JP JP2018524831A patent/JP6942126B2/ja active Active
- 2016-11-14 PL PL16801984T patent/PL3377109T3/pl unknown
- 2016-11-14 WO PCT/EP2016/077566 patent/WO2017085007A1/en active Application Filing
- 2016-11-15 US US15/351,510 patent/US10086003B2/en active Active
-
2018
- 2018-05-14 CL CL2018001297A patent/CL2018001297A1/es unknown
- 2018-05-14 IL IL259327A patent/IL259327B/en active IP Right Grant
- 2018-05-14 SA SA518391574A patent/SA518391574B1/ar unknown
- 2018-05-14 ZA ZA2018/03167A patent/ZA201803167B/en unknown
- 2018-05-15 PH PH12018501023A patent/PH12018501023B1/en unknown
- 2018-05-16 CO CONC2018/0005139A patent/CO2018005139A2/es unknown
- 2018-08-27 US US16/113,051 patent/US10786451B2/en active Active
- 2018-12-12 HK HK18115947.2A patent/HK1256859A1/zh unknown
-
2020
- 2020-04-08 HR HRP20200571TT patent/HRP20200571T1/hr unknown
- 2020-08-06 US US16/986,796 patent/US10959944B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211599T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20210704T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| HRP20211598T1 (hr) | Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik | |
| HRP20221432T1 (hr) | Formulacija suhog praška koja sadrži antikolinergik, kortikosteroid i beta-adrenergik za davanje inhalacijom | |
| RU2012145762A (ru) | Способ получения частиц с пониженным электростатическим зарядом | |
| RU2012149459A (ru) | Способ обработки частиц активных фармацевтических ингредиентов | |
| JP2018537453A5 (hr) | ||
| JP2019501876A5 (hr) | ||
| JP2013542940A5 (hr) | ||
| RU2015100905A (ru) | Сухой порошок для ингаляционного препарата, включающий сальметерола ксинафоат, флутиказона пропионат и тиотропия бромид, а также способ его изготовления | |
| JP2013507429A5 (hr) | ||
| JP2015519356A5 (hr) | ||
| HRP20200618T1 (hr) | Metoda za pripremu inhalacijskih pripravaka suhog praha | |
| JP2012509922A5 (hr) | ||
| CN104644618A (zh) | 一种干粉吸入剂及其制备方法 | |
| Pinto et al. | Insights into the processability and performance of adhesive blends of inhalable jet-milled and spray dried salbutamol sulphate at different drug loads | |
| AU2013275641B2 (en) | Method for producing powder for inhalation | |
| PT2821061T (pt) | Novas formulações para inalação | |
| EA201591871A1 (ru) | Фармацевтическая композиция, содержащая будесонид и формотерол | |
| WO2013109214A1 (en) | Process for the preparation of dry powder formulations | |
| JP2014104068A (ja) | 吸入用パウダーの製造方法 | |
| MX2017004583A (es) | Composicion farmaceutica que contiene budesonida y formoterol. | |
| JP2014105173A (ja) | 吸入用パウダーの製造方法 | |
| JP2014070067A (ja) | 吸入用パウダーの製造方法 | |
| TW201618759A (zh) | 具有經改善之組合型活性成分之穩定性的吸入型調配物乾粉末 |